Drug–Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)

Abstract

Lipid-lowering agents and antiplatelet drugs are guideline-recommended standard treatment for secondary prevention of acute thrombotic events in patients with increased cardiovascular risk. Aspirin is the most frequently used antiplatelet drug, either alone or in combination with other antiplatelet agents (P2Y₁₂ inhibitors), while statins are first-line treatment of hypercholesterolemia. The well-established mode of action of aspirin is inhibition of platelet-dependent thromboxane formation. In addition, aspirin also improves endothelial oxygen defense via enhanced NO formation and inhibits thrombin formation. Low-dose aspirin exerts in addition anti-inflammatory effects, mainly via inhibition of platelet-initiated activation of white cells.

Statins inhibit platelet function via reduction of circulating low-density lipoprotein-cholesterol (LDL-C) levels and a more direct inhibition of platelet function. This comprises inhibition of thromboxane formation via inhibition of platelet phospholipase A₂ and inhibition of (ox)LDL-C-mediated increases in platelet reactivity via the (ox)LDL-C receptor (CD36). Furthermore, statins upregulate endothelial NO-synthase and improve endothelial oxygen defense by inhibition of NADPH-oxidase. PCSK9 antibodies target a serine protease (PCSK9), which promotes the degradation of the LDL-C receptor impacting on LDL-C plasma levels and (ox)LDL-C-receptor-mediated signaling in platelets similar to but more potent than statins.

These functionally synergistic actions are the basis for numerous interactions between antiplatelet and these lipid-lowering drugs, which may, in summary, reduce the incidence of atherothrombotic vascular events.

Keywords

antiplatelet drugs - aspirin - PCSK9 - statins

^* Authors contributed equally to the manuscript (shared main authorship)

Publikationsverlauf

Eingereicht: 01. März 2022

Angenommen: 23. September 2022

Artikel online veröffentlicht:
15. Dezember 2022

• References

• 1 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
• 2 Lordan R, Tsoupras A, Zabetakis I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents. Blood Rev 2021; 45: 100694
• 3 Hohlfeld T, Schrör K. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?. Thromb Haemost 2015; 114 (03) 469-477
• 4 Manson JE, Grobbee DE, Stampfer MJ. et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990; 89 (06) 772-776
• 5 Ridker PM, Cook NR, Lee IM. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13) 1293-1304
• 6 Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J 1991; 122 (06) 1588-1592
• 7 Goldhaber SZ, Manson JE, Stampfer MJ. et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340 (8812): 143-145
• 8 West LE, Steiner T, Judge HM, Francis SE, Storey RF. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 2014; 102 (03) 429-435
• 9 Yourman LC, Cenzer IS, Boscardin WJ. et al. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis. JAMA Intern Med 2021; 181 (02) 179-185
• 10 Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open 2019; 9 (04) e023085
• 11 Cai T, Abel L, Langford O. et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021; 374 (1537): n1537
• 12 Hennekens CH, Sacks FM, Tonkin A. et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med 2004; 164 (01) 40-44
• 13 Gallone G, Baldetti L, Pagnesi M. et al. Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72 (23, Pt A): 2886-2903
• 14 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 74 (10) e177-e232
• 15 Sanz-Cuesta BE, Saver JL. Lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors. Stroke 2021; 52 (10) 3142-3150
• 16 Nenna A, Nappi F, Lusini M. et al. Effect of statins on platelet activation and function: from molecular pathways to clinical effects. BioMed Res Int 2021; 2021: 6661847
• 17 Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb 2017; 24 (05) 462-472
• 18 Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost 2019; 119 (03) 359-367
• 19 Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: Looking beyond LDL regulation. Eur J Clin Invest 2021; 51 (04) e13459
• 20 Barale C, Melchionda E, Morotti A, Russo I. PCSK9 biology and its role in atherothrombosis. Int J Mol Sci 2021; 22 (11) 5880
• 21 Pęczek P, Leśniewski M, Mazurek T, Szarpak L, Filipiak KJ, Gąsecka A. Antiplatelet effects of PCSK9 inhibitors in primary hypercholesterolemia. Life (Basel) 2021; 11 (06) 466
• 22 Puccini M, Landmesser U, Rauch U. Pleiotropic effects of PCSK9: focus on thrombosis and haemostasis. Metabolites 2022; 12 (03) 226
• 23 Camera M, Rossetti L, Barbieri SS. et al. PCSK9 as positive modulator of platelet activation. J Am Coll Cardiol 2018; 71 (08) 952-954
• 24 Petersen-Uribe Á, Kremser M, Rohlfing AK. et al. Platelet-derived PCSK9 is associated with LDL metabolism and modulates atherothrombotic mechanisms in coronary artery disease. Int J Mol Sci 2021; 22 (20) 11179
• 25 Qi Z, Hu L, Zhang J. et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation 2021; 143 (01) 45-61
• 26 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
• 27 Schwartz GG, Steg PG, Szarek M. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379 (22) 2097-2107
• 28 Schrör K, Löbel P, Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989; 2 (01) 39-45
• 29 Kaczmarek D, Hohlfeld T, Wambach G, Schrör K. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study. Eur J Clin Pharmacol 1993; 45 (05) 451-457
• 30 Luzak B, Boncler M, Rywaniak J. et al. The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. Eur J Pharmacol 2011; 658 (2–3): 91-97
• 31 Zhao Q, Li M, Chen M. et al. Lovastatin induces platelet apoptosis. Environ Toxicol Pharmacol 2016; 42: 69-75
• 32 Tacconelli S, Dovizio M, Di Francesco L. et al. Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. Clin Pharmacol Ther 2018; 104 (01) 111-119
• 33 Sexton TR, Wallace EL, Macaulay TE. et al. The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol 2015; 65 (03) 306-307
• 34 Moscardó A, Vallés J, Latorre A, Madrid I, Santos MT. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thromb Res 2013; 131 (04) e154-e159
• 35 Mattiello T, Guerriero R, Lotti LV. et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011; 58 (07) 752-761
• 36 Santos MT, Fuset MP, Ruano M, Moscardó A, Valles J. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009; 104 (12) 1618-1623
• 37 Bliden KP, Singla A, Gesheff MG. et al. Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Thromb Haemost 2014; 112 (02) 323-331
• 38 Chaudhary R, Bliden KP, Garg J. et al. Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. J Diabetes Complications 2016; 30 (07) 1365-1370
• 39 Konishi T, Funayama N, Yamamoto T. et al. Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis. Heart Vessels 2018; 33 (11) 1311-1324
• 40 Sexton T, Wallace EL, Smyth SS. Anti-thrombotic effects of statins in acute coronary syndromes: at the intersection of thrombosis, inflammation, and platelet-leukocyte interactions. Curr Cardiol Rev 2016; 12 (04) 324-329
• 41 Puccetti L, Pasqui AL, Pastorelli M. et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90 (03) 476-482
• 42 Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105 (12) 1446-1452
• 43 Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation 2017; 136 (13) 1183-1192
• 44 Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J 2006; 151 (05) 976.e1-976.e6
• 45 Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN. Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017; 40 (10) 887-893
• 46 Valdes V, Nardi MA, Elbaum L, Berger JS. Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. J Thromb Thrombolysis 2015; 40 (01) 83-87
• 47 Jayaram P, Yeh P, Patel SJ. et al. Effects of aspirin on growth factor release from freshly isolated leukocyte-rich platelet-rich plasma in healthy men: a prospective fixed-sequence controlled laboratory study. Am J Sports Med 2019; 47 (05) 1223-1229
• 48 Polzin A, Rassaf T, Böhm A. et al. Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction. Int J Cardiol 2013; 170 (02) e23-e24
• 49 Ulrych T, Böhm A, Polzin A. et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011; 9 (04) 790-798
• 50 Nomura S, Fujita S, Ozasa R. et al. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 2011; 22 (05) 396-397
• 51 Kang R, Chen R, Zhang Q. et al. HMGB1 in health and disease. Mol Aspects Med 2014; 40: 1-116
• 52 Mardente S, Mari E, Massimi I. et al. From human megakaryocytes to platelets: effects of aspirin on high-mobility group box 1/receptor for advanced glycation end products axis. Front Immunol 2018; 8: 1946
• 53 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231 (25) 235-237
• 54 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22 (09) 1381-1389
• 55 Tarantino E, Amadio P, Squellerio I. et al. Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model. Pharmacol Res 2016; 107: 415-425
• 56 Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man–effect of low-dose aspirin. Thromb Haemost 1987; 57 (01) 62-66
• 57 Undas A, Brummel-Ziedins K, Mann KG. Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thromb Haemost 2014; 12 (11) 1776-1787
• 58 Szczeklik A, Krzanowski M, Góra P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80 (08) 2006-2011
• 59 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16 (08) 948-954
• 60 Sanguigni V, Pignatelli P, Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111 (04) 412-419
• 61 Khattab AA, Ndrepepa G, Schulz S. et al. Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clin Res Cardiol 2011; 100 (07) 579-585
• 62 Serebruany VL, Miller M, Pokov AN. et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 2006; 97 (09) 1332-1336
• 63 Schrör K. Acetylsalicylic Acid. 3rd ed.. Berlin: de Gruyter; 2022
• 64 McClelland S, Gawaz M, Kennerknecht E. et al. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 2009; 202 (01) 84-91
• 65 Praticò D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271 (25) 14916-14924
• 66 Audoly LP, Rocca B, Fabre JE. et al. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101 (24) 2833-2840
• 67 Schwedhelm E, Bierend A, Maas R. et al. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. J Thromb Haemost 2010; 8 (12) 2662-2670
• 68 Violi F, Pignatelli P. Statins as regulators of redox signaling in platelets. Antioxid Redox Signal 2014; 20 (08) 1300-1312
• 69 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14) 973-979
• 70 Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98 (08) 731-733
• 71 Ridker PM, Danielson E, Fonseca FA. et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
• 72 Eisenhardt SU, Habersberger J, Murphy A. et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105 (02) 128-137
• 73 Puccetti L, Santilli F, Pasqui AL. et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011; 214 (01) 122-128
• 74 Fisher M, Cushman M, Knappertz V, Howard G. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J 2008; 156 (01) 106-111
• 75 Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143 (01) 159-165
• 76 O'Kane P, Xie L, Liu Z. et al. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 2009; 83 (01) 123-130
• 77 Grosser N, Abate A, Oberle S. et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 2003; 308 (04) 956-960
• 78 Grosser N, Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol 2003; 23 (08) 1345-1351
• 79 Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 2005; 289 (03) C557-C563
• 80 Hennekens CH, Schneider WR, Pokov A. et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010; 15 (04) 344-348
• 81 Hetzel S, DeMets D, Schneider R. et al. Aspirin increases nitric oxide formation in chronic stable coronary disease. J Cardiovasc Pharmacol Ther 2013; 18 (03) 217-221
• 82 Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004; 200 (01) 69-78
• 83 Laufs U, Gertz K, Huang P. et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31 (10) 2442-2449
• 84 Loboda A, Jazwa A, Grochot-Przeczek A. et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2008; 10 (10) 1767-1812
• 85 Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med 2014; 24 (04) 142-148
• 86 Navarese EP, Kolodziejczak M, Winter MP. et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol 2017; 227: 644-649
• 87 Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354 (12) 1264-1272
• 88 Leander K, Mälarstig A, Van't Hooft FM. et al. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation 2016; 133 (13) 1230-1239
• 89 Gurbel PA, Navarese EP, Tantry US. Exploration of PCSK9 as a cardiovascular risk factor: is there a link to the platelet?. J Am Coll Cardiol 2017; 70 (12) 1463-1466
• 90 Kasichayanula S, Grover A, Emery MG. et al. Clinical Pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet 2018; 57 (07) 769-779
• 91 Sahebkar A, Simental-Mendía LE, Guerrero-Romero F, Golledge J, Watts GF. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab 2015; 17 (11) 1042-1055
• 92 Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 (Suppl): S172-S177
• 93 Zhang DW, Lagace TA, Garuti R. et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282 (25) 18602-18612
• 94 Barale C, Bonomo K, Frascaroli C. et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up. Nutr Metab Cardiovasc Dis 2020; 30 (02) 282-291
• 95 Ding Z, Wang X, Liu S. et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res 2018; 114 (13) 1738-1751
• 96 Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM. et al. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother 2019; 5 (04) 237-245
• 97 Silverman MG, Ference BA, Im K. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316 (12) 1289-1297
• 98 Werner C, Hoffmann MM, Winkler K, Böhm M, Laufs U. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol 2014; 62 (02) 94-102
• 99 Cammisotto V, Pastori D, Nocella C. et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation. Antioxidants 2020; 9 (04) 296
• 100 Podrez EA, Byzova TV, Febbraio M. et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007; 13 (09) 1086-1095
• 101 Giugliano RP, Pedersen TR, Park JG. et al; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390 (10106): 1962-1971
• 102 Fitzgerald K, White S, Borodovsky A. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017; 376 (01) 41-51
• 103 German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs 2020; 34 (01) 1-9
• 104 Musunuru K. Treating coronary artery disease: beyond statins, ezetimibe, and PCSK9 inhibition. Annu Rev Med 2021; 72: 447-458